The honourable Prime Minister of India, Shri
Narendra Modi, has announced the introduction of four new vaccines as
part of India’s Universal Immunization Programme (UIP) [1].The decision
of the Government of India (GOI) was based on the recommendations of the
National Technical Advisory Group on Immunization (NTAGI), the country’s
apex scientific advisory body on immunization, which met in New Delhi in
June 2014. The Indian Academy of Pediatrics (IAP) was honoured to be one
of the invitees for this prestigious meeting.
The newest entrant in the UIP is the Rotavirus
vaccine which will be introduced in phases, in parallel with evaluation
of the results of post-marketing surveillance and pilot observational
study of the recently licensed indigenous 116E strain vaccine. The
recommendation is based on the huge burden of rotaviral diarrhea in the
country, with estimated 11.37 million episodes requiring 3.27 million
outpatient visits, 872,000 inpatient admissions and 78,000 deaths
annually [2]. Despite the reported low vaccine efficacy (55-60%) in
developing countries, introduction of rotavirus vaccine is expected to
avert the diarrhea-related morbidity and mortality significantly.
After the historic declaration of India as polio free
in March 2014, as part of the global endgame strategic plan of
2013-2018, there will be a timeline based withdrawal of oral polio
vaccine (OPV) from the immunization program with globally synchronized
trivalent-OPV (tOPV) to bivalent-OPV (bOPV) switch, and simultaneous
introduction of injectable polio vaccine (IPV) as an additional dose at
14 weeks (with DPT3 and OPV3), tentatively by mid-2015.
India has committed to the elimination of Measles and
control of Rubella by the year 2020. Rubella vaccine will be introduced
as Measles-Rubella (MR) vaccine replacing both doses of the Measles
containing vaccine at 9 months and 16-24 months. Surveillance for
congenital rubella syndrome and serosurveys for disease tracking has
been taken up as other important strategies for the control and
elimination of rubella. Pediatricians are requested to report and
maintain records of rubella cases to support the Government survey. IAP
is contemplating to include Congenital Rubella Syndrome (CRS) in the
list of the diseases reported on idsurv.org. The IAP has also now
made a change – in line with the NTAGI decision – and now recommends MMR
in place of stand alone measles vaccine at 9 months. The IAP in the
Standing Technical Subcommittee (STSC) meeting in February 2014 argued
for inclusion of the Mumps vaccine in the UIP (MMR in place of MR) but
could not convince the government on the need.
The pentavalent vaccine which was rolled out in a
phased manner in eight states in India is likely to be introduced in
eleven other states by October 2014. The Adverse Events following
Immunization (AEFI) surveillance system in the country has been
strengthened and members are requested to report adverse events to this
system. Japanese Encephalitis vaccination will be introduced in adults
in endemic districts, based on substantial disease burden (one or more
confirmed cases among adults in the district).
To reiterate the Prime Minister’s own words: "The
introduction of four new lifesaving vaccines will play a key role in
reducing the childhood and infant mortality and morbidity in the
country. Many of these vaccines are already available through private
practitioners to those who can afford them. The government will now
ensure that the benefits of vaccination reach all sections of the
society, regardless of social and economic status." The IAP welcomes the
decision of the Government to introduce these vaccines in the UIP, and
extends its full fledged support to the Government in all the above
promising strategies for reducing childhood and infant mortality in the
country.
References
1. Government of India. The three new Vaccines
including indigenously developed rotavirus vaccine to be provided to all
Indian children.[Press release] 2014 July 03. Available from:
http://pib.nic.in/newsite/PrintRelease.aspx?relid= 106055. Accessed
August 10, 2014.
2. John J, Sarkar R, Muliyil J, Bhandari N, Maharaj
K. Bhan MK, et al. Rotavirus gastroenteritis in India, 2011-2013:
Revised estimates of disease burden and potential impact of vaccines.
Vaccine. 2014;32:A5-9.